Related Experiment Videos
Immunotoxins in cancer therapy
Ira Pastan1, Robert J Kreitman
1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA. pasta@helix.nih.gov
Current Opinion in Investigational Drugs (London, England : 2000)
|August 21, 2002
Summary
Several cancer-fighting antibodies are approved for therapy. Some, like rituximab, induce cell death alone, while others, such as trastuzumab, enhance chemotherapy. Most antibodies require a cytotoxic agent to effectively kill cancer cells.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Antibody therapy is an emerging strategy for cancer treatment.
- Approved antibodies include rituximab, alemtuzumab, and trastuzumab, each with distinct mechanisms.
- The efficacy of some antibodies as monotherapy is limited.
Purpose of the Study:
- To review the therapeutic potential of approved cancer-fighting antibodies.
- To discuss the mechanisms by which antibodies induce tumor regression.
- To explore strategies for enhancing antibody-mediated cancer cell killing.
Main Methods:
- Review of existing literature on antibody-based cancer therapies.
- Analysis of clinical data for approved antibodies like rituximab, alemtuzumab, and trastuzumab.
- Discussion of antibody-drug conjugates and other "armed" antibody strategies.
Main Results:
- Rituximab and alemtuzumab demonstrate efficacy as standalone treatments, inducing cell death and tumor regression.
- Trastuzumab shows limited efficacy alone but potentiates chemotherapy, such as paclitaxel.
- Most antibodies require conjugation with cytotoxic agents (radioisotopes, drugs, toxins) for effective cancer cell elimination, each with specific advantages and drawbacks.
Conclusions:
- Approved antibodies offer diverse therapeutic approaches in oncology.
- Combining antibodies with cytotoxic payloads is a key strategy to overcome limitations in monotherapy.
- Further research into optimizing antibody conjugation holds promise for improved cancer treatment outcomes.